Literature DB >> 26629757

Clinical Applications for EPs in the ICU.

Matthew A Koenig1, Peter W Kaplan.   

Abstract

In critically ill patients, evoked potential (EP) testing is an important tool for measuring neurologic function, signal transmission, and secondary processing of sensory information in real time. Evoked potential measures conduction along the peripheral and central sensory pathways with longer-latency potentials representing more complex thalamocortical and intracortical processing. In critically ill patients with limited neurologic exams, EP provides a window into brain function and the potential for recovery of consciousness. The most common EP modalities in clinical use in the intensive care unit include somatosensory evoked potentials, brainstem auditory EPs, and cortical event-related potentials. The primary indications for EP in critically ill patients are prognostication in anoxic-ischemic or traumatic coma, monitoring for neurologic improvement or decline, and confirmation of brain death. Somatosensory evoked potentials had become an important prognostic tool for coma recovery, especially in comatose survivors of cardiac arrest. In this population, the bilateral absence of cortical somatosensory evoked potentials has nearly 100% specificity for death or persistent vegetative state. Historically, EP has been regarded as a negative prognostic test, that is, the absence of cortical potentials is associated with poor outcomes while the presence cortical potentials are prognostically indeterminate. In recent studies, the presence of middle-latency and long-latency potentials as well as the amplitude of cortical potentials is more specific for good outcomes. Event-related potentials, particularly mismatch negativity of complex auditory patterns, is emerging as an important positive prognostic test in patients under comatose. Multimodality predictive algorithms that combine somatosensory evoked potentials, event-related potentials, and clinical and radiographic factors are gaining favor for coma prognostication.

Entities:  

Mesh:

Year:  2015        PMID: 26629757     DOI: 10.1097/WNP.0000000000000215

Source DB:  PubMed          Journal:  J Clin Neurophysiol        ISSN: 0736-0258            Impact factor:   2.177


  6 in total

Review 1.  Brainstem Monitoring in the Neurocritical Care Unit: A Rationale for Real-Time, Automated Neurophysiological Monitoring.

Authors:  James L Stone; Julian E Bailes; Ahmed N Hassan; Brian Sindelar; Vimal Patel; John Fino
Journal:  Neurocrit Care       Date:  2017-02       Impact factor: 3.210

2.  Epidermal Electrode Technology for Detecting Ultrasonic Perturbation of Sensory Brain Activity.

Authors:  Stanley Huang; Jonathan A N Fisher; Meijun Ye; Yun-Soung Kim; Rui Ma; Marjan Nabili; Victor Krauthamer; Matthew R Myers; Todd P Coleman; Cristin G Welle
Journal:  IEEE Trans Biomed Eng       Date:  2017-08-29       Impact factor: 4.756

3.  Early impairment of intracranial conduction time predicts mortality in deeply sedated critically ill patients: a prospective observational pilot study.

Authors:  Eric Azabou; Benjamin Rohaut; Nicholas Heming; Eric Magalhaes; Régine Morizot-Koutlidis; Stanislas Kandelman; Jeremy Allary; Guy Moneger; Andrea Polito; Virginie Maxime; Djillali Annane; Frederic Lofaso; Fabrice Chrétien; Jean Mantz; Raphael Porcher; Tarek Sharshar
Journal:  Ann Intensive Care       Date:  2017-06-12       Impact factor: 6.925

Review 4.  Clinical neurophysiology for neurological prognostication of comatose patients after cardiac arrest.

Authors:  Andrea O Rossetti
Journal:  Clin Neurophysiol Pract       Date:  2017-03-20

5.  Functional and Prognostic Assessment in Comatose Patients: A Study Using Somatosensory Evoked Potentials.

Authors:  Andrea Victoria Arciniegas-Villanueva; Eva María Fernández-Diaz; Emilio Gonzalez-Garcìa; Javier Sancho-Pelluz; David Mansilla-Lozano; Tomás Segura
Journal:  Front Hum Neurosci       Date:  2022-07-04       Impact factor: 3.473

Review 6.  The Importance of Neuromonitoring in Non Brain Injured Patients.

Authors:  Denise Battaglini; Paolo Pelosi; Chiara Robba
Journal:  Crit Care       Date:  2022-03-22       Impact factor: 9.097

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.